Cargando…
A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care
The 2019 report of a randomized, placebo-controlled clinical trial demonstrating that immune therapy can delay the onset of clinical type 1 diabetes (T1D) in antibody-positive relatives by a median of 2 years stands out as a landmark in the decades-long effort to prevent T1D. With this important ste...
Autor principal: | Greenbaum, Carla J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173797/ https://www.ncbi.nlm.nih.gov/pubmed/33931405 http://dx.doi.org/10.2337/db20-1112 |
Ejemplares similares
-
Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes
por: Greenbaum, Carla J., et al.
Publicado: (2012) -
Uncovering Pathways to Personalized Therapies in Type 1 Diabetes
por: Linsley, Peter S., et al.
Publicado: (2021) -
β-Cell Growth and Regeneration: Replication Is Only Part of the Story
por: Bonner-Weir, Susan, et al.
Publicado: (2010) -
Human β-Cell Proliferation and Intracellular Signaling: Part 3
por: Stewart, Andrew F., et al.
Publicado: (2015) -
Immune Recognition of β-Cells: Neoepitopes as Key Players in the Loss of Tolerance
por: James, Eddie A., et al.
Publicado: (2018)